GPR30: a novel indicator of poor survival for endometrial carcinoma

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 4, 2007, Pages 386.e1-386.e11

  Smith, Harriet O ^a   Leslie, Kimberly K ^a   Singh, Meenakshi ^d   Qualls, Clifford R ^c   Revankar, Chetana M ^b   Joste, Nancy E ^b   Prossnitz, Eric R ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

endometrial carcinoma; estrogen receptor; GPR30; progesterone receptor; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; KI 67 ANTIGEN; PROGESTERONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYOMETRIUM; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33947697810     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.01.004     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 35 (2004) 649-662
3. Trimble C.L., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106 (2006) 812-819
4. Creasman W.T., Soper J.T., McCarty Jr. K.S., McCarty Sr. K.S., Hinshaw W., and Clarke-Pearson D.L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151 (1985) 922-932
5. Leslie K.K., Stein M.P., Kumar N.S., et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 96 (2005) 32-41
6. Khalifa M.A., Abdoh A.A., Mannel R.S., Haraway S.D., Walker J.L., and Min K.W. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73 (1994) 370-376
7. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 (1983) 10-17
8. Sutton G., Axelrod J.H., Bundy B.N., et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 97 (2005) 755-763
9. Randall M.E., Filiaci V.L., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24 (2006) 36-44
10. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
11. Ji T.H., Grossmann M., and Ji I. G protein-coupled receptors: I, diversity of receptor-ligand interactions. J Biol Chem 273 (1998) 17299-17302
12. Gether U., and Kobilka B.K. G protein-coupled receptors: II, mechanism of agonist activation. J Biol Chem 273 (1998) 17979-17982
13. Prossnitz E.R. Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. Life Sciences 75 (2004) 893-899
14. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16 (2002) 70-84
15. Ehrlich C.E., Young P.C., Stehman F.B., Sutton G.P., and Alford W.M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158 (1988) 796-807
16. Thigpen J.T., Brady M.F., Alvarez R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999) 1736-1744
17. Khalifa M.A., Mannel R.S., Haraway S.D., Walker J., and Min K.W. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53 (1994) 84-92
18. Niikura H., Sasano H., Matsunaga G., et al. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 26 (1995) 892-896
19. Albitar L., Laidler L.L., Abdallah R., and Leslie K.K. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 4 (2005) 1891-1899
20. Vivacqua A., Bonofiglio D., Recchia A.G., et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20 (2006) 631-646
21. Salvesen H.B., Iversen O.E., and Akslen L.A. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17 (1999) 1382-1390
22. Collett D. Modeling survival data in medical research (1994), Chapman & Hall, London
23. Bologa C.G., Revankar C.M., Young S.M., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2 (2006) 207-212
24. Rice L.W., Stone R.L., Xu M., et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mullerian tumors. Am J Obstet Gynecol 194 (2006) 1119-1128